18 F-fluorocholine PET/CT in MEN1 Patients with Primary Hyperparathyroidism
- PDF / 1,126,237 Bytes
- 9 Pages / 595.276 x 790.866 pts Page_size
- 42 Downloads / 145 Views
ORIGINAL SCIENTIFIC REPORT
18
F-fluorocholine PET/CT in MEN1 Patients with Primary Hyperparathyroidism
Mathieu Gauthe´1,2 • Anne Dierick-Gallet3 • Thierry Delbot4 • Le´opoldine Bricaire3 • Je´roˆme Bertherat3,5,6 • Marie-Odile North7 • Beatrix Cochand-Priollet8 • Phillipe Bouchard9 • Jean-Noe¨l Talbot1 • Lionel Groussin3,5,6 • Se´bastien Gaujoux5,6,10
Accepted: 5 July 2020 Ó Socie´te´ Internationale de Chirurgie 2020
Abstract Background Primary hyperparathyroidism (HPT1) is the most frequent endocrinopathy in multiple endocrine neoplasia type 1 (MEN1). Its surgical management is challenging. We aimed to describe and compare the imaging findings of parathyroid ultrasound (US), sestaMIBI scintigraphy (sestaMIBI), and 18F-fluorocholine (FCH) PET/CT in a series of MEN1 patients with HPT1. Methods Retrospective analysis of a cohort of MEN1 patients with HPT1 assessed by parathyroid US, sestaMIBI scintigraphy and SPECT/CT, and FCH-PET/CT for potential surgery between 2015 and 2019. Results Twenty-two patients with a confirmed diagnosis of MEN1 who presented with HPT1 and were assessed by the 3 imaging modalities were included. After imaging workups, 11 patients were operated on for the first time, 4 underwent a redo surgery, and 7 did not undergo an operation. The overall patient-based positivity rate of imaging was 91% (20 of 22) for parathyroid US and 96% (21 of 22) for both sestaMIBI and FCH-PET/CT. The 3 imaging modalities demonstrated negative findings in 1/22 patient who did not undergo surgery. Overall, 3 pathologic glands were not detected by any imaging technique. SestaMIBI and FCH-PET/CT both resulted in the same 3 false-positive results in ectopic areas with a significant uptake on two thymic carcinoid tumors and one inflammatory lymph node. FCH-PET/CT provided more surgically relevant data than sestaMIBI in 4/11 patients with initial surgery and in 1/4 patient who underwent redo surgery. Conclusions Compared to sestaMIBI scintigraphy, FCH-PET/CT provides additional information regarding the number of pathologic parathyroid glands and their localization in MEN1 patients with HPT1.
Lionel Groussin and Se´bastien Gaujoux should be viewed as co-last authors
Electronic supplementary material The online version of this article (https://doi.org/10.1007/s00268-020-05695-9) contains supplementary material, which is available to authorized users. & Lionel Groussin [email protected] 1
2
AP-HP Health Economics Research Unit, INSERM UMR 1153-CRESS METHODS, Paris, France
3
Department of Endocrinology, Hoˆpital Cochin, Assistance Publique-Hoˆpitaux de Paris, Universite´ de Paris, 27, rue du Faubourg Saint Jacques, 75014 Paris, France
4
Department of Nuclear Medicine, Hoˆpital Cochin, Assistance Publique-Hoˆpitaux de Paris, Paris, France
5
Universite´ de Paris, Paris, France
Department of Nuclear Medicine, Hoˆpital Tenon, Assistance Publique-Hoˆpitaux de Paris, Sorbonne Universite´, Paris, France
123
World J Surg
Introduction
Materials and methods
Primary hyperparathyroidism (HPT1) is the most fre
Data Loading...
